scholarly article | Q13442814 |
P50 | author | Mariana Lazarini | Q54376664 |
Fernanda Marconi Roversi | Q87070778 | ||
Sara Teresinha Olalla Saad | Q89663109 | ||
P2093 | author name string | Adriana da Silva Santos Duarte | |
Fernando Vieira Pericole | |||
Fernanda Soares Niemann | |||
Karla Priscila Vieira Ferro | |||
Luciana Bueno de Paiva | |||
P2860 | cites work | The bromodomain protein Brd4 insulates chromatin from DNA damage signalling | Q24294320 |
Selective inhibition of BET bromodomains | Q24301009 | ||
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 | ||
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes | Q46438891 | ||
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. | Q49963122 | ||
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Q29617201 | ||
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. | Q33601156 | ||
Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. | Q33767762 | ||
Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. | Q34485631 | ||
Revised international prognostic scoring system for myelodysplastic syndromes | Q34639717 | ||
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. | Q34772133 | ||
Bromodomain-Containing Protein 4: A Dynamic Regulator of Breast Cancer Metastasis through Modulation of the Extracellular Matrix | Q35684573 | ||
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts | Q35859212 | ||
Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure | Q35879437 | ||
BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell | Q35967957 | ||
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer | Q36862936 | ||
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. | Q36926120 | ||
High level of BRD4 promotes non-small cell lung cancer progression | Q36962647 | ||
Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA? | Q37060144 | ||
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition | Q37220129 | ||
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes | Q37571585 | ||
DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis | Q37977244 | ||
Epigenetics of myelodysplastic syndromes | Q38163846 | ||
Stem cell origin of myelodysplastic syndromes | Q38171230 | ||
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma in melanoma | Q38630705 | ||
The DNA damage-induced cell death response: a roadmap to kill cancer cells | Q38704734 | ||
Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias | Q38709586 | ||
BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells | Q38799987 | ||
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia | Q38837834 | ||
BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma | Q38894148 | ||
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. | Q39033630 | ||
BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. | Q39036236 | ||
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia | Q39063991 | ||
DNMT1 deficiency triggers mismatch repair defects in human cells through depletion of repair protein levels in a process involving the DNA damage response. | Q39531551 | ||
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. | Q43102402 | ||
Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients | Q44347691 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
acute myeloid leukemia | Q264118 | ||
azacitidine | Q416451 | ||
P304 | page(s) | 16 | |
P577 | publication date | 2019-01-29 | |
P1433 | published in | Frontiers in Oncology | Q26839986 |
P1476 | title | BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes | |
P478 | volume | 9 |
Q98471230 | BRD4 prevents the accumulation of R-loops and protects against transcription-replication collision events and DNA damage |
Q91825095 | BRD4 promotes tumor progression and NF-κB/CCL2-dependent tumor-associated macrophage recruitment in GIST |
Q92856196 | Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia |
Q94948764 | Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis |
Q90281630 | Functional Analysis of the Replication Fork Proteome Identifies BET Proteins as PCNA Regulators |
Q89884153 | Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML |
Search more.